azacitidine and Disease Exacerbation

azacitidine has been researched along with Disease Exacerbation in 172 studies

Research

Studies (172)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (1.16)	18.2507
2000's	38 (22.09)	29.6817
2010's	119 (69.19)	24.3611
2020's	13 (7.56)	2.80

Authors

Authors	Studies
Li, X; Yu, Q	1
Chen, J; Chen, Z; Chi, J; Deng, M; Hu, J; Huang, L; Li, J; Li, Q; Luo, Z; Tao, K; Wang, G; Wang, L; Wang, Z; Zhang, H; Zhou, C	1
Chen, N; Cheng, L; Dai, L; Deng, H; Dong, Z; Fang, C; Fu, J; Ji, Y; Li, J; Liu, Y; Shi, G; Su, X; Wang, H; Wang, W; Yang, Y; Yu, Y; Zhang, H; Zhang, S	1
Asnafi, V; Bardet, V; Benhamou, M; Bouscary, D; Carmeliet, G; Carvalho, C; Castaigne, S; Cheok, M; de Thé, H; Decroocq, J; Dombret, H; Ginzburg, YZ; Hermine, O; Lieben, L; Maciel, TT; Macintyre, E; Monteiro, RC; Moura, IC; Mupo, A; Paubelle, E; Preudhomme, C; Sujobert, P; Tamburini, J; Vassiliou, GS; Yokoyama, A; Zylbersztejn, F	1
Kowluru, RA; Mohammad, G	1
Adès, L; Angeli, E; Bally, C; Calleja, A; Chevallier, P; Cluzeau, T; Fenaux, P; Garnier, A; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Ngo Nloga, AM; Peterlin, P	1
Greil, R; Leisch, M; Pleyer, L	1
An, X; Cai, W; Guo, C; Li, M; Miao, W; Wang, B; Wei, J; Zhang, C; Zhang, F	1
Breccia, M; Colafigli, G; Di Prima, A; Diverio, D; Foà, R; Latagliata, R; Mancini, M; Martelli, M; Pepe, S; Scalzulli, E	1
Demehri, S; Ghim, SJ; Ha, T; Jenson, AB; Joh, JJ; Khanal, S; Redman, RA; Strickley, JD	1
Feng, Y; Li, Y; Liu, H; Liu, X; Luo, H; Ma, S; Ren, X; Shi, Y; Wang, Z; Xie, M; Yan, Y; Yang, H; Yi, C; Zhang, Q; Zhang, Y	1
Balleari, E; Campelo, MD; Fenaux, P; Germing, U; Götze, KS; Guerci-Bresler, A; Hamel, JF; Kelaidi, C; Komrokji, R; Kotsianidis, I; Park, S; Santini, V; Sanz, GF; Sekeres, MA; Stamatoullas, A; Steensma, D; Thépot, S; Toma, A	1
Bazani, E; Bouchla, A; Diamantopoulos, PT; Foukas, P; Galanopoulos, A; Gkontopoulos, K; Glezou, I; Kontandreopoulou, CN; Kontsioti, F; Kotsianidis, I; Lamprianidou, E; Mpakou, V; Mpamias, A; Papageorgiou, S; Pappa, V; Spathis, A; Symeonidis, A; Thomopoulos, T; Tsakiraki, Z; Viniou, NA; Zafeiropoulou, K	1
Breier, A; Elefantová, K; Janotka, Ľ; Kavcová, H; Messingerová, L; Šimoničová, K; Sulová, Z	1
Beelen, D; Bethge, W; Bleckert, G; Buchner, H; Bug, G; Giagounidis, A; Haase, D; Heinzelmann, M; Kobbe, G; Kröger, N; Krönke, J; Nolte, F; Platzbecker, U; Schäfer-Eckart, K; Scheid, C; Schlenk, RF; Sockel, K; Stadler, M; Stelljes, M; Wolf, D; Wolschke, C; Wulf, G	1
Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E	1
Alessandrino, EP; Candoni, A; Carella, AM; Cerqui, E; Cortelezzi, A; Criscuolo, M; Fianchi, L; Finelli, C; Leone, G; Masciulli, A; Molteni, A; Parma, M; Piciocchi, A; Poloni, A; Rambaldi, A; Salvi, F; Santarone, S; Sica, S; Spina, F; Voso, MT	1
Guo, H; Li, XX; Lin, J; Ma, JC; Qian, J; Wen, XM; Yan, Y; Yang, L; Zhang, TJ; Zhang, W; Zhou, JD	1
Nohgawa, M; Oka, S; Ono, K	2
Baker, K; Deeg, HJ; Festuccia, M; Gooley, TA; Sandmaier, BM; Scott, BL	1
Chen, M; Dong, L; Feng, K; Han, W; Jia, H; Li, X; Liu, L; Liu, Y; Mei, Q; Nie, J; Shi, L; Zhang, Y	1
Fujiwara, S; Katayama, Y; Kawano, H; Matsui, T; Nakano, H; Nishigori, C; Taketani, S; Yoshioka, A	1
Ahn, JS; Bae, SH; Cho, YY; Chung, JS; Kim, H; Kim, HJ; Kim, SH; Kim, YS; Kwon, JH; Lee, HS; Lee, IH; Lee, JH; Lee, SM; Lee, WS; Lee, YJ; Moon, JH; Park, SW; Shin, HJ; Sohn, SK; Song, IC	1
Deng, C; Du, X; Geng, S; Lai, P; Li, M; Lu, Z; Weng, J; Wu, P	1
Darwish, HA; Diab, I; Helmy, MW; Motawi, TK; Noureldin, MH	1
Chang, GS; DiPersio, JF; Duncavage, EJ; Elliott, K; Fronick, CC; Fulton, RS; Graubert, TA; Heath, SE; Jacoby, MA; Ley, TJ; Link, DC; Miller, CA; O'Laughlin, M; Pusic, I; Robinson, J; Shao, J; Walter, MJ; Welch, JS; Westervelt, P	1
Ding, C; Dong, Z; Guo, W; Guo, Y; Liang, J; Liu, S; Shan, B; Shen, S	1
Fan, Y; Guo, F; Song, D; Sun, Q; Wang, J; Wang, L; Zhang, D; Zhang, Q; Zhang, W	1
Matei, D; Mitra, AK; Mitra, S; Nephew, KP; Wang, Y; Zong, X	1
Cui, Y; Ding, M; Gao, Y; Li, X; Li, Y; Singh, N; Tian, R; Wu, X; Yang, Y	1
Boasman, K; Graham, C; Rinaldi, CR; Saunthararajah, Y; Simmonds, MJ	1
Liu, J; Liu, L; Liu, X; Zhang, S	1
Davoudi, B; Ekström, TJ; Estekizadeh, A; Hu, LF; Landázuri, N; Nawaz, I; Pantalone, MR; Rahbar, A; Stragliotto, G	1
Chen, G; Chen, H; Dong, Z; Liu, H; Liu, Y; Ren, S; Sun, L; Tang, L; Xia, M; Zhang, L; Zhu, J	1
Bernard, E; Bezirgiannidou, Z; Kordella, C; Kotsianidis, I; Lamprianidou, E; Papaemmanuil, E; Papoutselis, M; Vrachiolias, G; Zoulia, E	1
Seiter, K	1
Antonicelli, F; Diederich, M; Doliwa, C; Dufer, J; Poplineau, M; Schnekenburger, M; Trussardi-Régnier, A	1
Brown, CO; Fitzgerald, MP; Goel, A; Salem, K; Schibler, J; Singh, N; Zhan, F	1
Benet, B; Billot, K; d'Allard, D; Ettou, S; Fontenay, M; Goodhardt, M; Humbrecht, C; Kosmider, O; Mariot, V; Mayeux, P; Solary, E	1
Bastian, L; Haberthür, R; Menter, T; Rätz Bravo, AE; Schlageter, M; Tzankov, A	1
Brioli, A; Davies, FE; Johnson, DC; Kaiser, MF; Melchor, L; Mirabella, F; Morgan, GJ; Walker, BA; Wardell, CP; Wu, P	1
Bultmann, I; Conradi, A; Kretschmer, C; Sterner-Kock, A	1
Guinea de Castro, JM; Moreno de Gusmão, B; Oiartzabal, I; Perez-Persona, E	1
Devaney, JM; Funda, S; Furbert-Harris, P; Ittmann, M; Kwabi-Addo, B; Long, J; Taghipour, DJ; Tbaishat, R; Wang, S	1
Berger, F; Bertoni, F; Cavalli, F; Cogliatti, S; Forconi, F; Gaidano, G; Gattei, V; Kwee, I; Lucioni, M; Marasca, R; Mensah, AA; Orlandi, EM; Rinaldi, A; Rossi, D; Zucca, E	1
Al Ali, NH; Duong, VH; Komrokji, RS; Kumar, A; Lancet, JE; Lin, K; List, AF; Reljic, T	1
Benedetti, D; Bomben, R; Caldana, C; D'Arena, G; Dal Bo, M; Del Poeta, G; Di Raimondo, F; Gaidano, G; Gattei, V; Hartmann, TN; Hutterer, E; Pozzato, G; Pozzo, F; Rossi, D; Rossi, FM; Tissino, E; Zaja, F; Zucchetto, A	1
Egle, A; Melchardt, T; Weiss, L	1
Angioli, R; Barbosa, A; Begum, S; Brait, M; de Graeff, P; Fazio, VM; Hoque, MO; Loyo, M; Maldonado, L; Marchionni, L; Noordhuis, M; Noordhuis, MG; Poeta, ML; Rabitti, C; Sidransky, D; van der Zee, AG; Wisman, GB	1
Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S	1
Douvali, E; Kotsianidis, I; Margaritis, D; Papadopoulos, V; Papoutselis, M; Spanoudakis, E; Tsatalas, C	1
Cai, LL; Chi, XH; Li, SW; Lu, XC; Ran, HH; Wang, HT; Yang, B; Yang, Y; Yu, RL; Zhao, Y; Zhu, HL	1
Han, J; Heo, K; Hong, SH; Hwang, JA; Kim, DH; Kim, Y; Kim, YH; Lee, BB; Lee, YS; Park, SE; Shim, YM	1
Baylin, SS; Belinsky, SA; Liu, Y; Tellez, CS; Tessema, M; Van Neste, L; Yingling, CM	1
Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E	1
Tohyama, K	1
Burgstaller, S; Geissler, D; Germing, U; Girschikofsky, M; Greil, R; Lang, A; Linkesch, W; Mitrovic, M; Neureiter, D; Pfeilstocker, M; Placher-Sorko, G; Pleyer, L; Schlick, K; Schreder, M; Sliwa, T; Sperr, WR; Stauder, R; Thaler, J; Theiler, G; Valent, P	1
Bai, SY; Jiao, F; Ma, Y; Wang, J; Wang, X; Yan, ZH; Yu, Y; Yue, Z	1
Santini, V	1
Cornelison, AM; Cortes, JE; Daver, N; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Ravandi, F; Teng, A	1
Schleiffenbaum, BE	1
Cao, Z; Chen, S; Cheng, Y; Dong, M; Fan, X; Feng, X; Gao, Y; Jin, Z; Liu, J; Meltzer, SJ; Mori, Y; Wang, L; Wu, W; Yu, H; Zhang, X; Zhao, Z	1
Gao, H; Gu, J; Ren, L; Wang, X; Zhang, Y	1
Kanashima, H; Nakao, T; Sugiyama, H; Ueda, H; Yamane, T; Yoshida, M	1
Cupelli, L; de Fabritiis, P; Del Poeta, G; Dentamaro, T; Giovannini, M; Niscola, P; Piccioni, D; Scaramucci, L; Tendas, A	1
Chu, TY; Ding, DC; Huang, RL; Lin, CJ; Liu, CJ; Liu, DW; Wang, KH; Weng, CF	1
Han, L; Jiang, K; Kang, C; Liu, X; Ning, X; Shi, Z; Zhang, A; Zhang, Q	1
Mukherjee, S; Ornstein, MC; Sekeres, MA	1
Adès, L; Berthon, C; Braun, T; Brechignac, S; Cherait, A; Fenaux, P; Gardin, C; Harel, S; Park, S; Quesnel, B; Rigal, M; Thépot, S; Willekens, C	1
Chim, CS; Li, ZY; Wang, LQ; Wong, KY; Zhang, Q	1
Jiang, P; Lee, S; Lee, W; Xiang, Y; Yu, G; Zhang, C; Zhang, Y; Zhu, Z	1
Amigo, ML; Ardanaz, MT; Bargay, J; Benlloch, L; Bernal, T; Brunet, S; de Paz, R; del Cañizo, C; Luño, E; Martínez-Camblor, P; Nomdedeu, B; Pedro, C; Sánchez-García, J; Sanz, G; Tormo, M; Valcárcel, D; Xicoy, B	1
Alimena, G; Andriani, A; Andrizzi, C; Ciccone, F; De Gregoris, C; Di Veroli, A; Latagliata, R; Maurillo, L; Montanaro, M; Villivà, N; Voso, MT	1
Akers, SN; Barger, CJ; Karpf, AR; Link, PA; Mhawech-Fauceglia, P; Miller, A; Odunsi, K; Zhang, W	1
Bakarakos, P; Diamantopoulos, P; Dimitrakopoulou, A; Galanopoulos, A; Giannakopoulou, N; Iliakis, T; Kalala, F; Papadopoulou, V; Rougala, N; Variami, E; Viniou, NA; Zervakis, K	1
Garcia-Manero, G	1
Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP	1
Choi, CW; Do, YR; Jang, JH; Jeong, SH; Joo, YD; Kim, HG; Kim, I; Kim, SJ; Kim, SR; Kim, YJ; Kim, YK; Lee, JH; Lee, WS; Mun, YC; Na, SM; Park, SK; Yi, HG	1
Aul, C; Baron, F; Becker, H; Bogatyreva, L; de Witte, T; Ganser, A; Germing, U; Giagounidis, A; Hagemeijer, A; Huls, G; Labar, B; Lübbert, M; Marie, JP; Muus, P; Pflüger, KH; Platzbecker, U; Rüter, B; Salih, HR; Schaefer, HE; Selleslag, D; Suciu, S; van der Helm, L; Vellenga, E; Wijermans, PW	1
Fujimaki, K; Kawasaki, R; Miyashita, K; Tomita, N	1
Ding, L; Jin, LY; Kong, B; Lv, ZD; Wang, Y; Yang, ZC	1
Cheng, JC; Chiang, MT; Chiu, KC; Chou, YT; Huang, RY; Huang, SM; Lee, CH; Liu, SY; Shieh, YS	1
Agodi, A; Borghesan, M; Buschbeck, M; Cappello, F; Douet, J; Faulkes, C; Fusilli, C; Mazza, T; Mazzoccoli, G; Minogue, S; Oben, JA; Panebianco, C; Pata, I; Pazienza, V; Peterson, A; Rappa, F; Rezaee, F; Rizzo, G; Sedivy, JM; Vinciguerra, M; Warren, A	1
Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L	1
Carter, CA; Day, RM; Lybeck, M; Oronsky, A; Oronsky, B; Oronsky, N; Richard, P; Scicinski, J; Zeman, K	1
Amler, L; Bourgon, R; Frierson, H; Fu, L; Fuentes, E; Hampton, GM; Kabbarah, O; Lackner, MR; Lu, S; Moskaluk, C; Okrah, K; Penuel, E; Pirzkall, A; Qu, X; Rumpel, C; Sandmann, T; Tabernero, J; Walter, K; Wang, Y	1
Navada, SC; Silverman, LR	1
He, Y; Huang, C; Huang, K; Li, Z; Liu, H; Ye, G; Zhou, X	1
Choi, YY; Kim, H; Kim, WK; Lee, JH; Lee, NK; Lee, SK; Park, CH; Youn, YH; Yun, S	1
Al Ali, N; Barnard, J; Brown, F; DeZern, AE; Garcia-Manero, G; Hand, W; Komrokji, RS; Roboz, GJ; Sekeres, MA; Steensma, DP; Zeidan, AM; Zimmerman, C	1
Chen, L; Gong, F; Guo, Y; Jin, J; Li, R; Ma, RZ; Niu, Y; Shi, X; Zhang, L; Zhang, X	1
Kim, MC; Kim, NY; Kim, Y	1
Abaza, Y; Anz, B; Babu, S; Berdeja, JG; Boccia, R; DeZern, AE; Essell, J; Garcia-Manero, G; Ghalie, R; Heller, B; Jabbour, E; Kantarjian, HM; Komrokji, RS; Kuriakose, P; Lyons, RM; Maris, M; Montalban-Bravo, G; Ravandi, F; Reeves, J; Roboz, GJ; Sekeres, MA; Wright, D	1
Stahl, M; Zeidan, AM	1
Chiba, H; Nakayama, F; Sawada, N; Semba, S; Usami, Y; Yokozaki, H	1
Chen, H; El-Rifai, W; Peng, DF; Razvi, M; Roessner, A; Schneider-Stock, R; Washington, K	1
Kim, J; Kim, WH; Lee, SH; Lee, YM	1
Champlin, R; Davisson, J; de Lima, M; De Padua Silva, L; Faderl, S; Garcia-Manero, G; Giralt, S; Issa, JP; Kantarjian, H; Kebriaei, P; Ravandi, F	1
Bronson, R; Charest, A; Coven, S; Housman, D; Jun, HJ; Lane, K; Woolfenden, S	1
Bertz, H; Claus, R; Finke, J; Lübbert, M; Marks, R; Rüter, B; Wäsch, R	1
Stone, RM	1
Gorantla, B; Knost, JA; Pulukuri, SM; Rao, JS	1
Ibrahim, SM; Kunz, M; Schultz, J; Vera, J	1
Dahiya, R; Hinoda, Y; Hirata, H; Ishii, N; Kawakami, K; Kawamoto, K; Kikuno, N; Majid, S; Nakajima, K; Saini, S; Ueno, K; Yamamura, S	1
Chang, JK; Chang, LH; Chen, CH; Fu, YC; Ho, ML; Hung, SH; Lee, HY; Lin, YS; Wang, GJ; Wu, SC	1
Becker, PS; Deeg, HJ; Estey, EH; Petersdorf, S; Ramakrishnan, A; Scott, BL; Storer, B	1
Chen, BH; Hsu, HS; Lee, SH; Tsai, WC; Tseng, RC; Tzao, C; Wang, YC	1
Jang, YK; Park, SH; Yu, SE	1
Bentov, I; Plymate, SR; Schayek, H; Sun, S; Werner, H	1
Garcia-Manero, G; Quintás-Cardama, A; Santos, FP	1
Buckstein, R; Wells, RA; Yee, K	1
Adès, L; Chait, Y; Cluzeau, T; Dartigeas, C; Delaunay, J; Dreyfus, F; Eclache, V; Fenaux, P; Harel, S; Itzykson, R; Kiladjian, JJ; Quesnel, B; Raffoux, E; Salanoubat, C; Sanhes, L; Seegers, V; Sorin, L; Thepot, S; Turlure, P	1
Garcia-Manero, G; Martin-Santos, T; Vigil, CE	1
Jang, YK; Park, SH; Shin, JE	1
Cai, HH; Gao, WT; Miao, Y; Peng, Q; Sun, YM; Yao, J; Zhao, HL	1
Chen, EX; Egorin, MJ; Espinoza-Delgado, I; Hirte, HW; Holleran, JL; Hotte, SJ; Laughlin, A; McGill, S; Moretto, P; Oza, AM; Siu, LL; Stathis, A; Stayner, LA; Wang, L; Webster, S; Zhang, WJ	1
Alajez, NM; Bruce, J; Huang, SH; Hui, AB; Ito, E; Lenarduzzi, M; Liu, FF; O'Sullivan, B; Shi, W; Waldron, J; Xu, W; Yue, S	1
Bernardini, S; Corso, G; Cretella, M; Del Vecchio Blanco, G; Di Cecilia, S; Federici, G; Formosa, A; Kalimutho, M; Marrelli, D; Pallone, F; Roviello, F; Sileri, P	1
Criscuolo, M; D'Alo, F; Fianchi, L; Greco, M; Hohaus, S; Leone, G; Pagano, L; Voso, MT	1
Chu, SH; Feng, DF; Jiang, PC; Li, ZQ; Ma, YB; Zhang, H; Zhu, ZA	1
Chae, YS; Kang, BW; Kim, JG; Lee, SJ; Lee, YJ; Moon, JH; Sohn, SK; Suh, JS	1
Chang, X; Chen, J; Dai, D; Ma, J; Zhang, S; Zhi, Y	1
Chim, CS; Jin, DY; Liang, R; So, CC; Wong, KY; Yim, RL	1
Carducci, MA; Herman, JG; Shabbeer, S; Simons, BW; Williams, SA	1
Hiraishi, T; Itoh, F; Maehata, T; Niwa, H; Oikawa, R; Oishi, Y; Sato, Y; Suzuki, H; Suzuki, M; Toyota, M; Watanabe, Y; Yoshida, Y	1
Alimena, G; Breccia, M; Loglisci, G; Mancini, M; Petrucci, L; Salaroli, A; Serrao, A	1
Groen, RW; Kersten, MJ; Kocemba, KA; Mahtouk, K; Pals, ST; Spaargaren, M; van Andel, H	1
Altendorf-Hofmann, A; Chen, Y; Hotovy, S; Knösel, T; Petersen, I; Settmacher, U	1
Baylin, SB; Belinsky, SA; Brock, MV; Coleman, B; Delgado, IE; Franco, N; Herman, JG; Hooker, CM; Juergens, RA; Lee, B; Murphy, SC; Rodgers, K; Rudek, MA; Rudin, CM; Sebree, R; Tsai, S; Vendetti, FP; Wrangle, J; Zhao, M	1
Hu, C; Jin, J; Tong, H; Wang, L; Zhuang, Z	1
Ritchie, EK	1
Cornfield, DB	1
Brower, V	1
Bernardo, V; da Silva, DC; de Souza, CF; Jasiulionis, MG; Lopes, JD; Mai, S; Monteiro, AC; Silva, AG; Xander, P	1
Bernal, T; Gutiérrez-Fernández, A; Moncada-Pazos, A; Soria-Valles, C	1
Esteban, S; Fernandez-Suarez, A; Maestro, M; Morente, M; Moya, P; Sánchez-Carbayo, M	1
Cortes, JE; Faderl, S; Fullmer, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Wierda, W	1
Chi, SG; Lee, MG; Ryu, BK; Yoo, TH	1
Czepulkowski, B; Gäken, J; Ireland, R; Krishnamurthy, P; Kulasekararaj, AG; Lea, NC; Marsh, JC; Mian, SA; Mohamedali, AM; Mufti, GJ; Pennaneach, C; Pomplun, S; Smith, AE	1
Battistini, A; Belardelli, F; Fragale, A; Gabriele, L; Lucarini, V; Mattei, F; Sanchez, M; Scala, S; Schiavoni, G; Sestili, P; Sistigu, A; Spada, M; Spadaro, F	1
Allen, PB; Baer, MR; Kleinberg, ME; Koka, R	1
Alimena, G; Bari, A; Breccia, M; Fianchi, L; Finelli, C; Leone, G; Lunghi, M; Musto, P; Niscola, P; Poloni, A; Voso, MT; Zambello, R	1
Brown, J; Felix, DH; Fleming, J; Harrison, PR; MacDonald, DG; McGregor, F; Muntoni, A; Parkinson, EK	1
Daskalakis, M; Guldberg, P; Jones, PA; Köhler, G; Lübbert, M; Nguyen, C; Nguyen, TT; Wijermans, P	1
Demers, M; Magnaldo, T; Mercier, J; Moisan, S; Potworowski, EF; St-Pierre, Y	1
Frants, RR; Gruis, NA; Hurks, MHMH; Jager, MJ; Krijgsman, E; Ksander, BR; Pavey, S; Tensen, CP; van der Velden, PA; Willemze, R; Zuidervaart, W	1
Bukawa, H; Miyakawa, A; Mochida, Y; Nakatsuru, M; Ono, K; Shiiba, M; Tada, A; Tanzawa, H; Uzawa, K; Yokoe, H	1
Endoh, M; Honda, T; Motoyama, T; Nishizuka, S; Tamura, G; Yanagawa, N	1
Anast, JW; Bassett, WW; Carroll, PR; Dahiya, R; Enokida, H; Igawa, M; Kane, CJ; Kawahara, M; Kawakami, T; Li, LC; Nakagawa, M; Ogishima, T; Shiina, H; Terashima, M; Urakami, S; Verma, M	1
Ito, R; Nakayama, H; Oda, N; Yasui, W; Yoshida, K	1
Fukushima, A; Hata, T; Koeffler, HP; Mori, N; Seo, H; Taguchi, H; Takeuchi, S; Tsukasaki, K; Yamada, Y; Yang, Y	1
Bilchik, AJ; Fujimoto, A; Hoon, DS; Shinozaki, M; Takeuchi, H; Umetani, N	1
Breault, JE; Carroll, PR; Dahiya, R; Deguchi, M; Enokida, H; Igawa, M; Kane, CJ; Nakagawa, M; Ribeiro-Filho, LA; Shiina, H; Terashima, M; Urakami, S	1
Bergin, OE; Brown, R; Byrne, A; Culhane, AC; Currid, CA; Dervan, PA; Easty, DJ; Esteller, M; Fox, EJ; Fraga, MF; Gallagher, WM; Hughes, L; Kelly, ZD; McArdle, L; McDonnell, S; Moss, C; Murphy, AA; Nolan, IM; O'Mahony, F; Plumb, JA; Rafferty, M; Stallings, RL	1
Flores-Morales, A; Johansson, B; Larsson, C; Nilsson, P; Norstedt, G; Pang, ST; Pourian, MR; Pousette, A; Weng, WH	1
Benhattar, J; Bosman, FT; Braunschweig, R; Clément, G; Pasquier, N	1
Albitar, M; Bennett, JM; de Castro, C; DiPersio, J; Helmer, R; Issa, JP; Kantarjian, H; Klimek, V; Leavitt, R; Nimer, SD; Ravandi, F; Raza, A; Rosenfeld, CS; Saba, H; Shen, L; Slack, J	1
Lübbert, M; Rüter, B; Wijermans, PW	1
Pampalakis, G; Sotiropoulou, G	1
Hoon, DS; Kitago, M; Martinez, SR; Mori, T; Morton, DL; Nguyen, SL; O'Day, SJ; Tanemura, A; Tran, AN; Umetani, N; Wang, HJ	1
Blaschke, B; Knobbe, CB; Reifenberger, G; van den Boom, J; Wolter, M	1
Abraham, JM; Cheng, Y; Greenwald, BD; Hamilton, JP; Ito, T; Jin, Z; Kan, T; Meltzer, SJ; Mori, Y; Paun, BC; Sato, F; Wang, S; Yang, J	1
Druck, T; Fabbri, M; Han, SY; Huebner, K; Iliopoulos, D; Qin, HR	1
Cui, X; Liu, T; Meng, WT; Xi, YM; Ye, XS	1
Callet-Bauchu, E; Emura, M; Groenen, P; Kamphues, K; Lehmann, U; Ripperger, T; Rudolph, C; Schlegelberger, B; Schraders, M; Skawran, B; Steinemann, D; Tauscher, M; van Krieken, JH; von Neuhoff, N	1
Fitzgerald, RC; Gjerset, RA; Huang, Y; Peters, CJ	1
Chen, XP; Gutmann, DH; Huang, ZY; Xiao, ZY; Xiong, M; Yan, Q; Zhang, ZF	1
Chen, PW; Ksander, BR; Murray, TG; Reddy, R; Salgaller, ML; Uno, T	1
Fenaux, P; Quesnel, B	1
Bertram, JS; Donlon, TA; Fukushima, LH; Hieber, AD; King, TJ; Shimabukuro, KA	1
den Hollander, AI; Ruiter, DJ; van Kraats, AA; van Muijen, GN; Weidle, UH; Zendman, AJ	1

Reviews

12 review(s) available for azacitidine and Disease Exacerbation

Article	Year
[Myelodysplastic syndromes: treatment strategy up-to-date]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:1 Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles	2014
More is better: combination therapies for myelodysplastic syndromes. Best practice & research. Clinical haematology, 2015, Volume: 28, Issue:1 Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat	2015
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. American journal of hematology, 2015, Volume: 90, Issue:9 Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Disease Management; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Thalidomide; Transplantation, Homologous	2015
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. Oncotarget, 2016, Jun-28, Volume: 7, Issue:26 Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; CpG Islands; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histones; Humans; Hydralazine; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Nitro Compounds; Nivolumab; Prognosis; Pyridines; Treatment Outcome; Valproic Acid	2016
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes. Expert review of anticancer therapy, 2016, Volume: 16, Issue:8 Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndromes; Prognosis; Sulfones; Survival Rate; Treatment Outcome	2016
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer, 2017, 05-15, Volume: 123, Issue:10 Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 5; Disease Progression; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome	2017
How I treat patients with myelodysplastic syndromes. Blood, 2009, Jun-18, Volume: 113, Issue:25 Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous	2009
Therapy with azanucleosides for myelodysplastic syndromes. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:8 Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 7; Decitabine; Deoxycytidine; Disease Progression; DNA Methylation; Drug Therapy, Combination; Humans; Myelodysplastic Syndromes; Risk Assessment; Treatment Outcome	2010
5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline. Cancer treatment reviews, 2011, Volume: 37, Issue:2 Topics: Age Factors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Disease Progression; Humans; Myelodysplastic Syndromes; Practice Guidelines as Topic; Quality of Life	2011
Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug design, development and therapy, 2010, Sep-24, Volume: 4 Topics: Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Survival	2010
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome. Clinical interventions in aging, 2012, Volume: 7 Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytarabine; Disease Progression; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality of Life; Risk Assessment; Sickness Impact Profile	2012
P15INK4b gene methylation and myelodysplastic syndromes. Leukemia & lymphoma, 1999, Volume: 35, Issue:5-6 Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 9; Clinical Trials, Phase II as Topic; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Decitabine; Disease Progression; DNA Methylation; Genes, p16; Genes, Tumor Suppressor; Hematopoiesis; Humans; Leukemia, Myeloid; Mice; Myelodysplastic Syndromes; Neoplasm Proteins; Precancerous Conditions; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transforming Growth Factor beta; Tumor Suppressor Proteins	1999

Trials

13 trial(s) available for azacitidine and Disease Exacerbation

Article	Year
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 10-20, Volume: 39, Issue:30 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Progression-Free Survival; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous	2021
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jul-01, Volume: 28, Issue:7 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult	2017
Increased IFNγ Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Oct-15, Volume: 23, Issue:20 Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cytotoxicity, Immunologic; Decitabine; Disease Models, Animal; Disease Progression; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Female; Humans; Interferon-gamma; Lymphocyte Activation; Male; Mice; Neoplasms; Survival Analysis; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Th1 Cells; Treatment Outcome; Xenograft Model Antitumor Assays	2017
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Annals of hematology, 2016, Volume: 95, Issue:2 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; Female; Germany; Humans; Leukemia; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Risk Factors	2016
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer, 2017, May-15, Volume: 123, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Biomarkers; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Treatment Outcome	2017
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone marrow transplantation, 2009, Volume: 43, Issue:11 Topics: Adult; Aged; Azacitidine; Decitabine; Disease Progression; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2009
Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone marrow transplantation, 2009, Volume: 44, Issue:9 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate; Transplantation Conditioning	2009
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. British journal of haematology, 2010, Volume: 148, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease Progression; Etanercept; Female; Humans; Immunoglobulin G; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Tumor Necrosis Factor; Remission Induction; Treatment Outcome	2010
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood, 2010, Nov-11, Volume: 116, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; France; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Philadelphia Chromosome; Prognosis; Treatment Outcome	2010
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-15, Volume: 17, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Humans; Hydroxamic Acids; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Promoter Regions, Genetic; Time Factors; Vorinostat	2011
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer discovery, 2011, Volume: 1, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Disease Progression; Disease-Free Survival; DNA Methylation; Epigenesis, Genetic; Female; Genetic Therapy; Histones; Humans; Lung Neoplasms; Male; Middle Aged; Pyridines	2011
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 2006, Apr-15, Volume: 106, Issue:8 Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; DNA Methylation; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Survival Rate	2006
Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer, 2006, Apr-15, Volume: 106, Issue:8 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Risk Factors; Survival Rate	2006

Other Studies

147 other study(ies) available for azacitidine and Disease Exacerbation

Article	Year
PON1 hypermethylation is associated with progression of renal cell carcinoma. Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aryldialkylphosphatase; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; CpG Islands; Databases, Genetic; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Kidney Neoplasms; Mice; Mice, Nude; Sunitinib; Transplantation, Heterologous	2019
AGR2 is controlled by DNMT3a-centered signaling module and mediates tumor resistance to 5-Aza in colorectal cancer. Experimental cell research, 2019, 12-01, Volume: 385, Issue:1 Topics: Azacitidine; Caco-2 Cells; Carcinogenesis; Cell Line; Cell Line, Tumor; Colorectal Neoplasms; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; HEK293 Cells; HT29 Cells; Humans; Mucoproteins; Oncogene Proteins; Prognosis; Promoter Regions, Genetic; Signal Transduction; Up-Regulation	2019
Temporal DNA methylation pattern and targeted therapy in colitis-associated cancer. Carcinogenesis, 2020, 04-22, Volume: 41, Issue:2 Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Azoxymethane; bcl-Associated Death Protein; Carcinogenesis; Cell Line, Tumor; Colitis; Colon; Colonoscopy; Colorectal Neoplasms; Decitabine; Disease Models, Animal; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Intestinal Mucosa; Male; Mice; Molecular Targeted Therapy; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Up-Regulation	2020
Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. Cell reports, 2020, 01-21, Volume: 30, Issue:3 Topics: Animals; Apoptosis; Azacitidine; Bone Marrow; Cell Count; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Monocytes; Myeloid Cells; Neoplastic Stem Cells; Oncogenes; Promoter Regions, Genetic; Receptors, Calcitriol; Signal Transduction; Survival Analysis; Tumor Stem Cell Assay	2020
Epigenetics and Mitochondrial Stability in the Metabolic Memory Phenomenon Associated with Continued Progression of Diabetic Retinopathy. Scientific reports, 2020, 04-20, Volume: 10, Issue:1 Topics: Animals; Azacitidine; Cell Line; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; DNA, Mitochondrial; Electroretinography; Endothelial Cells; Epigenesis, Genetic; Glucose; GTP Phosphohydrolases; Humans; Hyperglycemia; Male; Mitochondria; MutL Protein Homolog 1; Rats; Rats, Wistar; Retina; RNA, Small Interfering; Signal Transduction; Streptozocin	2020
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients. British journal of haematology, 2020, Volume: 190, Issue:3 Topics: Abnormal Karyotype; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Diseases; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Febrile Neutropenia; Female; France; Hospitalization; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome	2020
IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target? British journal of haematology, 2020, Volume: 190, Issue:3 Topics: Azacitidine; Disease Progression; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pharmaceutical Preparations; Prognosis	2020
Tumor cell-expressed IL-15Rα drives antagonistic effects on the progression and immune control of gastric cancer and is epigenetically regulated in EBV-positive gastric cancer. Cellular oncology (Dordrecht), 2020, Volume: 43, Issue:6 Topics: Azacitidine; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Humans; Models, Biological; Neoplasm Invasiveness; Promoter Regions, Genetic; Receptors, Interleukin-15; Recombinant Proteins; RNA, Messenger; Stomach Neoplasms; Survival Analysis; Up-Regulation	2020
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. Annals of hematology, 2020, Volume: 99, Issue:10 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Cause of Death; Cell Count; Decitabine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA, Neoplasm; Female; Hemoglobins; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Proportional Hazards Models; Retrospective Studies; Treatment Outcome	2020
Human papillomavirus-positivity is associated with EREG down-regulation and promoter hypermethylation in head and neck squamous cell carcinoma. Experimental and molecular pathology, 2020, Volume: 117 Topics: Alphapapillomavirus; Azacitidine; Carcinogenesis; Cell Line, Tumor; Decitabine; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Epiregulin; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Promoter Regions, Genetic; Squamous Cell Carcinoma of Head and Neck	2020
Aberrant methylation‑mediated decrease of lncRNA HNF1A‑AS1 contributes to malignant progression of laryngeal squamous cell carcinoma via EMT. Oncology reports, 2020, Volume: 44, Issue:6 Topics: Aged; Animals; Azacitidine; Cell Line, Tumor; Chemotherapy, Adjuvant; CpG Islands; Disease Progression; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Laryngeal Neoplasms; Laryngectomy; Larynx; Lymphatic Metastasis; Male; Mice; Middle Aged; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays	2020
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leukemia research, 2020, Volume: 99 Topics: Activin Receptors, Type II; Aged; Anemia, Sideroblastic; Azacitidine; Disease Progression; Erythrocyte Transfusion; Erythropoietin; Female; Ferritins; Follow-Up Studies; Hematinics; Humans; Immunoglobulin Fc Fragments; Kaplan-Meier Estimate; Lenalidomide; Male; Proportional Hazards Models; Recombinant Fusion Proteins; Salvage Therapy; Treatment Failure	2020
Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group. Hematological oncology, 2021, Volume: 39, Issue:2 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Hypoxia-Inducible Factor 1; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Risk Factors; Up-Regulation	2021
Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents. International journal of molecular sciences, 2021, Feb-19, Volume: 22, Issue:4 Topics: Apoptosis; Azacitidine; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Survival; Decitabine; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Necrosis; Neoplasm Proteins; Promoter Regions, Genetic; Signal Transduction	2021
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14 Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid	2017
Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies. Journal of cellular and molecular medicine, 2017, Volume: 21, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Case-Control Studies; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; HL-60 Cells; Humans; Inhibitor of Differentiation Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Signal Transduction; Survival Analysis	2017
Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation. Annals of hematology, 2017, Volume: 96, Issue:8 Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; In Situ Hybridization, Fluorescence; Janus Kinase 2; Leukemia, Myeloid, Acute; Multiple Myeloma; Mutation, Missense; Neoplasms, Multiple Primary; Remission Induction; Translocation, Genetic	2017
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:9 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2017
Late-onset Erythropoietic Protoporphyria Associated with Myelodysplastic Syndrome Treated with Azacitidine. Acta dermato-venereologica, 2018, Feb-07, Volume: 98, Issue:2 Topics: Aged; Azacitidine; Disease Progression; Enzyme Inhibitors; Humans; Male; Myelodysplastic Syndromes; Protoporphyria, Erythropoietic; Skin; Treatment Outcome	2018
No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. The Korean journal of internal medicine, 2018, Volume: 33, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Databases, Factual; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult	2018
WT1 mRNA level reflects disease changes and progression of myelodysplastic syndromes patients with 'stable disease'. British journal of haematology, 2019, Volume: 184, Issue:3 Topics: Adult; Aged; Azacitidine; Decitabine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; RNA, Messenger; WT1 Proteins	2019
Combinatorial strategy of epigenetic and hormonal therapies: A novel promising approach for treating advanced prostate cancer. Life sciences, 2018, Apr-01, Volume: 198 Topics: Anticarcinogenic Agents; Azacitidine; beta Catenin; Caspase 3; Cell Proliferation; Cyclin D1; Decitabine; Disease Progression; Epigenesis, Genetic; Estrogen Receptor beta; Hormones; Humans; Hydroxamic Acids; Male; Methylation; Nitriles; Propionates; Prostate; Prostatic Neoplasms; Vascular Endothelial Growth Factor A	2018
Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI insight, 2018, 03-08, Volume: 3, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Clonal Evolution; Clone Cells; Disease Progression; DNA Mutational Analysis; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mutation; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2018
Aberrant methylation-mediated silencing of lncRNA CTC-276P9.1 is associated with malignant progression of esophageal squamous cell carcinoma. Clinical & experimental metastasis, 2018, Volume: 35, Issue:1-2 Topics: Adult; Aged; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; CpG Islands; Disease Progression; DNA Methylation; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gene Silencing; Humans; Luciferases; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Promoter Regions, Genetic; RNA, Long Noncoding; Sp1 Transcription Factor; Survival Analysis; Up-Regulation	2018
The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS. American journal of hematology, 2018, Volume: 93, Issue:9 Topics: Azacitidine; Bone Marrow Examination; Disease Progression; Female; Humans; Interleukin-6; Japan; Male; Monoclonal Gammopathy of Undetermined Significance; Myelodysplastic Syndromes; Myeloma Proteins; Retrospective Studies; Tumor Suppressor Protein p53	2018
Hypermethylated CD36 gene affected the progression of lung cancer. Gene, 2018, Dec-15, Volume: 678 Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; CD36 Antigens; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Invasiveness; Xenograft Model Antitumor Assays	2018
IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells. JCI insight, 2018, 12-06, Volume: 3, Issue:23 Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Azacitidine; Cell Line, Tumor; Cytokines; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Therapy; Epigenomics; Female; Humans; Immunotherapy; Interleukin-6; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neoplastic Stem Cells; Ovarian Neoplasms; Platinum; Retinal Dehydrogenase; Signal Transduction; STAT3 Transcription Factor; Tumor Microenvironment; Up-Regulation	2018
Promoter hypermethylation of SOX11 promotes the progression of cervical cancer in vitro and in vivo. Oncology reports, 2019, Volume: 41, Issue:4 Topics: Adult; Azacitidine; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cervix Uteri; CpG Islands; Disease Progression; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Promoter Regions, Genetic; SOXC Transcription Factors; Tumor Suppressor Proteins; Up-Regulation; Uterine Cervical Neoplasms	2019
Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation. Annals of hematology, 2019, Volume: 98, Issue:6 Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Biomarkers, Tumor; Bone Marrow; Cell Transformation, Neoplastic; Disease Progression; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Proto-Oncogene Proteins; Repressor Proteins; Trans-Activators; Up-Regulation	2019
Aberrant promoter 2 methylation‑mediated downregulation of protein tyrosine phosphatase, non‑receptor type 6, is associated with progression of esophageal squamous cell carcinoma. Molecular medicine reports, 2019, Volume: 19, Issue:4 Topics: Adult; Aged; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; CpG Islands; Disease Progression; DNA Methylation; Epigenesis, Genetic; Esophageal Squamous Cell Carcinoma; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 6	2019
5‑Azacytidine treatment results in nuclear exclusion of DNA methyltransferase‑1, as well as reduced proliferation and invasion in human cytomegalovirus‑infected glioblastoma cells. Oncology reports, 2019, Volume: 41, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cytomegalovirus; Cytoplasm; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; Treatment Outcome; Viral Envelope Proteins; Virus Replication	2019
Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease. Kidney international, 2019, Volume: 96, Issue:2 Topics: Adolescent; Adoptive Transfer; Adult; Aged; Animals; Azacitidine; Cytosine; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Epigenesis, Genetic; Female; Gene Knockdown Techniques; Humans; Leukocytes, Mononuclear; Male; Mice; Middle Aged; Primary Cell Culture; Promoter Regions, Genetic; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Young Adult	2019
Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma. Leukemia & lymphoma, 2019, Volume: 60, Issue:13 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Bone Marrow; Disease Progression; DNA Methylation; DNA Mutational Analysis; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Karyotyping; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Treatment Outcome	2019
Myelodysplasia: new approaches. Current treatment options in oncology, 2013, Volume: 14, Issue:2 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Stem Cell Transplantation	2013
Epigenetically induced changes in nuclear textural patterns and gelatinase expression in human fibrosarcoma cells. Cell proliferation, 2013, Volume: 46, Issue:2 Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Nucleus; Chromatin; Chromatin Assembly and Disassembly; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Fibrosarcoma; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Image Cytometry; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neoplasm Metastasis; Neoplasm Proteins	2013
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma. Leukemia research, 2013, Volume: 37, Issue:8 Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Decitabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Hydroxamic Acids; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidants; Prognosis; Pyrazines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Scavenger Receptors, Class A	2013
Epigenetic control of NF-κB-dependent FAS gene transcription during progression of myelodysplastic syndromes. Molecular cancer research : MCR, 2013, Volume: 11, Issue:7 Topics: Azacitidine; Base Sequence; Bone Marrow Cells; Cell Line, Tumor; Disease Progression; DNA Methylation; Epigenesis, Genetic; fas Receptor; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Myelodysplastic Syndromes; NF-kappa B; Nitriles; Promoter Regions, Genetic; Protein Binding; Sulfones; Transcription, Genetic	2013
Development of an Epstein-Barr virus-associated lymphoproliferative disorder in a patient treated with azacitidine for chronic myelomonocytic leukaemia. Hematological oncology, 2014, Volume: 32, Issue:1 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Bone Marrow; Combined Modality Therapy; Disease Progression; Epstein-Barr Virus Infections; Fatal Outcome; Female; Humans; Iatrogenic Disease; Leukemia, Myelomonocytic, Chronic; Lung; Lymph Nodes; Lymphoproliferative Disorders; Necrosis; Pneumonia; RNA, Viral; Spleen; Viral Matrix Proteins	2014
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood, 2013, Jul-11, Volume: 122, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Chromosome Aberrations; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; Middle Aged; Multiple Myeloma; Osteonectin; Phenotype; Prognosis; Transforming Growth Factor beta1; Tumor Suppressor Proteins	2013
Latent transforming growth factor β-binding protein 4 is downregulated in esophageal cancer via promoter methylation. PloS one, 2013, Volume: 8, Issue:5 Topics: Azacitidine; Base Sequence; Binding Sites; Carcinoma; Cell Line, Tumor; Cell Movement; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Gene Order; Humans; Latent TGF-beta Binding Proteins; Neoplasm Staging; Promoter Regions, Genetic; Protein Binding; Transcription Factors; Transforming Growth Factor beta1	2013
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors]. Medicina clinica, 2014, Jan-21, Volume: 142, Issue:2 Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles	2014
Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia. Prostate cancer and prostatic diseases, 2013, Volume: 16, Issue:4 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cluster Analysis; CpG Islands; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Grading; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Reproducibility of Results; Sequence Analysis, DNA	2013
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. British journal of haematology, 2013, Volume: 163, Issue:2 Topics: Azacitidine; Cell Cycle; Cell Transformation, Neoplastic; Cluster Analysis; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Epigenomics; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplastic Stem Cells; Oncostatin M; Promoter Regions, Genetic; Reproducibility of Results	2013
Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:6 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk; Treatment Failure; Treatment Outcome	2013
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood, 2013, Nov-07, Volume: 122, Issue:19 Topics: Azacitidine; B-Lymphocytes; Cell Proliferation; Cells, Cultured; Chromosomes, Human, Pair 12; Decitabine; Disease Progression; Gene Expression Regulation, Leukemic; Humans; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Methylation; Sequence Analysis, DNA; Signal Transduction; Survival Analysis; Trisomy	2013
[Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:41 Topics: Aged; Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Azacitidine; Biopsy, Needle; Bone Marrow; Diagnosis, Differential; Disease Progression; Follow-Up Studies; Humans; Leukopenia; Male; Myelodysplastic Syndromes; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia	2013
Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression. PloS one, 2013, Volume: 8, Issue:9 Topics: Adult; Aged; Azacitidine; Base Sequence; Cohort Studies; Decitabine; Disease Progression; DNA Methylation; DNA Primers; Female; Humans; Middle Aged; Nerve Growth Factors; Ovarian Neoplasms; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ubiquitin Thiolesterase	2013
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome]. Medicina clinica, 2014, Jul-07, Volume: 143, Issue:1 Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis	2014
Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience. Leukemia research, 2014, Volume: 38, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Professional Practice; Retrospective Studies; Survival Analysis	2014
Successful management of acute myeloid leukemia transformed from myelodysplastic syndromes in an elderly patient aged over 80 years old by ultralow dose decitabine combined with amifostine and autologous CIK cells. Annals of hematology, 2014, Volume: 93, Issue:7 Topics: Aged, 80 and over; Amifostine; Azacitidine; Cells, Cultured; Combined Modality Therapy; Cytokine-Induced Killer Cells; Decitabine; Disease Management; Disease Progression; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Transplantation, Autologous	2014
HOXA11 hypermethylation is associated with progression of non-small cell lung cancer. Oncotarget, 2013, Volume: 4, Issue:12 Topics: Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Decitabine; Disease Progression; DNA Methylation; Female; Homeodomain Proteins; Humans; Lung Neoplasms; Male; Middle Aged; Paraffin Embedding; Promoter Regions, Genetic; Transfection	2013
Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. Carcinogenesis, 2014, Volume: 35, Issue:6 Topics: Adenocarcinoma; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genome-Wide Association Study; Humans; Lung Neoplasms; Promoter Regions, Genetic; Reproducibility of Results; Smoking	2014
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leukemia research, 2014, Volume: 38, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult	2014
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia research, 2014, Volume: 38, Issue:4 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Matched-Pair Analysis; Middle Aged; Survival Analysis	2014
DNA methylation of heparanase promoter influences its expression and associated with the progression of human breast cancer. PloS one, 2014, Volume: 9, Issue:3 Topics: Azacitidine; Breast Neoplasms; Carcinogenesis; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Gene Expression Regulation, Neoplastic; Glucuronidase; Humans; MCF-7 Cells; Neoplasm Invasiveness; Promoter Regions, Genetic	2014
[Identification of myelodysplastic syndromes patients]. Recenti progressi in medicina, 2014, Volume: 105, Issue:3 Topics: Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Quality of Life; Risk Factors; Survival	2014
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leukemia & lymphoma, 2015, Volume: 56, Issue:2 Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Proportional Hazards Models; Retrospective Studies	2015
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly]. Praxis, 2014, May-21, Volume: 103, Issue:11 Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Diagnosis, Differential; Disease Progression; Hematopoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Thalidomide	2014
Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis. BMC cancer, 2014, May-20, Volume: 14 Topics: Adenocarcinoma; Area Under Curve; Azacitidine; Barrett Esophagus; Carcinoma, Squamous Cell; Caveolin 1; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; RNA, Messenger; ROC Curve; Time Factors	2014
Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer. BMC cancer, 2014, May-02, Volume: 14 Topics: Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Humans; Male; Methyltransferases; Mice; MicroRNAs; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays	2014
[Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:7 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	2014
Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting. Acta haematologica, 2015, Volume: 133, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation, Homologous; Treatment Failure	2015
Global methylation silencing of clustered proto-cadherin genes in cervical cancer: serving as diagnostic markers comparable to HPV. Cancer medicine, 2015, Volume: 4, Issue:1 Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Cadherins; Cell Adhesion; Cell Line, Tumor; CpG Islands; Disease Progression; DNA Methylation; Female; Gene Silencing; Genetic Loci; Humans; Middle Aged; Multigene Family; Neoplasm Invasiveness; Neoplasm Staging; Papillomaviridae; Papillomavirus Infections; Severity of Illness Index; Uterine Cervical Neoplasms	2015
DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer letters, 2015, Apr-10, Volume: 359, Issue:2 Topics: Adenosine; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Decitabine; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Histones; Humans; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Polycomb Repressive Complex 2; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays	2015
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia research, 2015, Volume: 39, Issue:5 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome	2015
Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma. Journal of clinical pathology, 2015, Volume: 68, Issue:7 Topics: Azacitidine; Biomarkers, Tumor; Case-Control Studies; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; MicroRNAs; Multiple Myeloma; Phenotype; Promoter Regions, Genetic; Recurrence; Treatment Outcome	2015
Increased expression of protease-activated receptor 4 and Trefoil factor 2 in human colorectal cancer. PloS one, 2015, Volume: 10, Issue:4 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Decitabine; Disease Progression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Microarray Analysis; Neoplasm Invasiveness; Peptides; Polymerase Chain Reaction; Receptors, Thrombin; Trefoil Factor-2	2015
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia, 2015, Volume: 29, Issue:9 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease Progression; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Registries; Spain; Treatment Outcome	2015
Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Leukemia research, 2015, Volume: 39, Issue:8 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Disease Progression; Female; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome	2015
DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Epigenetics, 2015, Volume: 10, Issue:8 Topics: Aged; Antigens, Neoplasm; Azacitidine; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Promoter Regions, Genetic; RNA, Messenger	2015
5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients. Anticancer research, 2015, Volume: 35, Issue:9 Topics: Aged; Aged, 80 and over; Azacitidine; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Treatment Outcome	2015
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. Leukemia & lymphoma, 2016, Volume: 57, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome	2016
A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. Oncotarget, 2015, Dec-29, Volume: 6, Issue:42 Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Febrile Neutropenia; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Republic of Korea; Risk Factors; Time Factors; Treatment Outcome; Young Adult	2015
Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes. European journal of haematology, 2016, Volume: 97, Issue:3 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Treatment Outcome	2016
Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:9 Topics: Adult; Azacitidine; Cell Line, Tumor; Cell Movement; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Repressor Proteins; RNA Interference; RNA, Messenger; Transfection; Triple Negative Breast Neoplasms	2015
γ-Synuclein Expression Is a Malignant Index in Oral Squamous Cell Carcinoma. Journal of dental research, 2016, Volume: 95, Issue:4 Topics: Azacitidine; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Disease Progression; DNA Methylation; gamma-Synuclein; Gene Expression; Humans; Mouth Neoplasms; Polymerase Chain Reaction; RNA, Messenger; Up-Regulation	2016
DNA Hypomethylation and Histone Variant macroH2A1 Synergistically Attenuate Chemotherapy-Induced Senescence to Promote Hepatocellular Carcinoma Progression. Cancer research, 2016, Feb-01, Volume: 76, Issue:3 Topics: Adult; Aged, 80 and over; Animals; Azacitidine; beta-Galactosidase; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cellular Senescence; Disease Progression; DNA Methylation; Epigenomics; Gene Expression; Hep G2 Cells; Histones; Humans; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Knockout; Protein Isoforms	2016
Autoimmune diseases and myelodysplastic syndromes. American journal of hematology, 2016, Volume: 91, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; Disease Susceptibility; Female; Follow-Up Studies; Hashimoto Disease; Humans; Immunocompromised Host; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prevalence; Proportional Hazards Models; Retrospective Studies; Thalidomide; Thyroiditis, Autoimmune; Young Adult	2016
Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter. Oncogene, 2016, 12-15, Volume: 35, Issue:50 Topics: Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; Disease Progression; DNA Methylation; Epiregulin; ErbB Receptors; Humans; Phosphorylation; Promoter Regions, Genetic	2016
Downregulation of thrombospondin-1 by DNA hypermethylation is associated with tumor progression in laryngeal squamous cell carcinoma. Molecular medicine reports, 2016, Volume: 14, Issue:3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Decitabine; Disease Progression; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Thrombospondin 1; Transcriptional Activation	2016
Promoter methylation of PCDH10 by HOTAIR regulates the progression of gastrointestinal stromal tumors. Oncotarget, 2016, 11-15, Volume: 7, Issue:46 Topics: Apoptosis; Azacitidine; Cadherins; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Promoter Regions, Genetic; Protocadherins; RNA, Long Noncoding	2016
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). Leukemia & lymphoma, 2017, Volume: 58, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Sex Factors; Treatment Outcome	2017
Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma. Oncotarget, 2017, Jan-03, Volume: 8, Issue:1 Topics: 5-Methylcytosine; Animals; Azacitidine; Cell Line, Tumor; Chromatin Immunoprecipitation; Decitabine; Dioxygenases; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Demethylation; DNA Methylation; DNA Methyltransferase 3A; DNA-Binding Proteins; Down-Regulation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Melanoma; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Promoter Regions, Genetic; Proto-Oncogene Proteins; RNA, Small Interfering; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays	2017
Hypomethylation reduced the aggressive potential of human malignant mesothelioma cells. Cancer gene therapy, 2016, Volume: 23, Issue:12 Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Survival; CpG Islands; Decitabine; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant	2016
Hypermethylation-modulated downregulation of claudin-7 expression promotes the progression of colorectal carcinoma. Pathobiology : journal of immunopathology, molecular and cellular biology, 2008, Volume: 75, Issue:3 Topics: Azacitidine; Cell Line, Tumor; Claudins; Colorectal Neoplasms; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Gene Expression; Humans; Lymph Nodes; Lymphatic Metastasis; Membrane Proteins; Methylation; Neoplasm Staging; Promoter Regions, Genetic	2008
DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. Gut, 2009, Volume: 58, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Barrett Esophagus; Cell Transformation, Neoplastic; CpG Islands; Decitabine; Disease Progression; DNA Methylation; DNA, Neoplasm; Down-Regulation; Epigenesis, Genetic; Esophageal Neoplasms; Gene Expression Regulation, Enzymologic; Glutathione Peroxidase; Glutathione Transferase; Humans; Hydroxamic Acids; Middle Aged; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured	2009
Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene, 2009, Jan-15, Volume: 28, Issue:2 Topics: Acetylation; Azacitidine; Cell Hypoxia; Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histocompatibility Antigens; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone-Lysine N-Methyltransferase; Humans; Hydroxamic Acids; Methylation; Neoplasm Proteins; Protein Processing, Post-Translational; Recombinant Fusion Proteins; Stomach Neoplasms; Transcription, Genetic	2009
Epigenetic regulation of c-ROS receptor tyrosine kinase expression in malignant gliomas. Cancer research, 2009, Mar-15, Volume: 69, Issue:6 Topics: Astrocytoma; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Microarray Analysis; Promoter Regions, Genetic; Proto-Oncogene Mas; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation	2009
Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. Oncogene, 2009, Aug-06, Volume: 28, Issue:31 Topics: Acetylation; Animals; Azacitidine; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromatin; Cystatin M; Decitabine; Disease Progression; DNA Methylation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasms, Experimental; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transplantation, Heterologous	2009
14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence. Molecular cancer, 2009, Jul-30, Volume: 8 Topics: 14-3-3 Proteins; Antineoplastic Agents; Azacitidine; Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Movement; Cellular Senescence; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Exonucleases; Exoribonucleases; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Melanoma; Neoplasm Metastasis; Neoplasm Proteins; Phenylbutyrates; RNA, Messenger	2009
Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Sep-15, Volume: 15, Issue:18 Topics: Adult; Aged; Apoptosis; Azacitidine; Carcinoma, Renal Cell; Cell Cycle; Chromatin Immunoprecipitation; Decitabine; Disease Progression; Female; Gene Silencing; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Middle Aged; Wnt Proteins	2009
Parathyroid hormone 1-34 inhibits terminal differentiation of human articular chondrocytes and osteoarthritis progression in rats. Arthritis and rheumatism, 2009, Volume: 60, Issue:10 Topics: Adult; Animals; Azacitidine; Cartilage, Articular; Cell Differentiation; Cell Proliferation; Cells, Cultured; Chondrocytes; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Female; Glycosaminoglycans; Humans; Injections, Intra-Articular; Male; Middle Aged; Osteoarthritis; Papain; Parathyroid Hormone; Rats; Rats, Sprague-Dawley	2009
SLIT2 attenuation during lung cancer progression deregulates beta-catenin and E-cadherin and associates with poor prognosis. Cancer research, 2010, Jan-15, Volume: 70, Issue:2 Topics: Azacitidine; beta Catenin; beta-Transducin Repeat-Containing Proteins; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Movement; Decitabine; Disease Progression; DNA Methylation; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Nerve Tissue Proteins; Oncogene Protein v-akt; Prognosis; Promoter Regions, Genetic; Receptors, Immunologic; RNA, Messenger; Roundabout Proteins	2010
Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer. Molecules and cells, 2010, Feb-28, Volume: 29, Issue:2 Topics: Azacitidine; Base Sequence; Breast Neoplasms; CD27 Ligand; Cell Line, Tumor; CpG Islands; Disease Progression; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Molecular Sequence Data; Promoter Regions, Genetic; RNA, Messenger	2010
Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Experimental cell research, 2010, May-15, Volume: 316, Issue:9 Topics: Androgen Antagonists; Androgens; Azacitidine; Blotting, Western; CpG Islands; Decitabine; Dihydrotestosterone; Disease Progression; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Promoter Regions, Genetic; Prostatic Neoplasms; Receptor, IGF Type 1; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured	2010
Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer. Molecules and cells, 2011, Volume: 31, Issue:2 Topics: 5' Flanking Region; Azacitidine; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; CpG Islands; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; Leukemia Inhibitory Factor; Methyl-CpG-Binding Protein 2; Molecular Sequence Data; Precancerous Conditions; Promoter Regions, Genetic; Protein Binding; RNA Interference; RNA, Messenger; Sp1 Transcription Factor; Tumor Stem Cell Assay; Up-Regulation	2011
Aberrant methylation frequency of TNFRSF10C promoter in pancreatic cancer cell lines. Hepatobiliary & pancreatic diseases international : HBPD INT, 2011, Volume: 10, Issue:1 Topics: Apoptosis; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression; GPI-Linked Proteins; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Promoter Regions, Genetic; Receptors, Tumor Necrosis Factor, Member 10c; Restriction Mapping; Sequence Analysis, DNA; Tumor Cells, Cultured; Tumor Necrosis Factor Decoy Receptors	2011
MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer research, 2011, Mar-15, Volume: 71, Issue:6 Topics: 3' Untranslated Regions; Adult; Aged; Azacitidine; Base Sequence; Cell Line; Cell Line, Tumor; Connexin 43; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Inhibitor of Apoptosis Proteins; Intercellular Signaling Peptides and Proteins; Male; MicroRNAs; Middle Aged; Molecular Sequence Data; Nasopharyngeal Neoplasms; Nerve Tissue Proteins; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; Roundabout Proteins; Signal Transduction; Survivin	2011
Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. British journal of cancer, 2011, May-24, Volume: 104, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Disease Progression; DNA Methylation; Feces; Female; Gene Silencing; Humans; Male; MicroRNAs; Middle Aged	2011
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule. Leukemia research, 2012, Volume: 36, Issue:1 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Humans; Male; Myelodysplastic Syndromes; Time Factors	2012
Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. Journal of translational medicine, 2011, Sep-21, Volume: 9 Topics: Animals; Astrocytes; Azacitidine; Blotting, Western; Brain; Cell Adhesion; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Progression; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Neoplasm Grading; Neurons; Oligodendroglia; Organic Cation Transport Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Recurrence; RNA, Messenger	2011
Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast. Annals of hematology, 2012, Volume: 91, Issue:3 Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Treatment Outcome	2012
Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression. Digestive diseases and sciences, 2012, Volume: 57, Issue:3 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Transformed; Cell Line, Tumor; Chemokine CXCL12; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Receptors, CXCR; Receptors, CXCR4; Stomach Neoplasms	2012
Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood, 2011, Nov-24, Volume: 118, Issue:22 Topics: Azacitidine; Base Sequence; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; Molecular Sequence Data; Multiple Myeloma; Primary Cell Culture; Recurrence; Tumor Cells, Cultured	2011
Progression of prostate carcinogenesis and dietary methyl donors: temporal dependence. Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:2 Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Choline; Decitabine; Diet; Disease Progression; DNA Methylation; Folic Acid; Homocysteine; Humans; Male; Methionine; Mice; Mice, Nude; Prostatic Neoplasms; Tumor Cells, Cultured; Vitamin B 6	2012
Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:2 Topics: Aged; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Early Detection of Cancer; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Risk; SOXF Transcription Factors; Stomach Neoplasms	2012
5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. Leukemia & lymphoma, 2012, Volume: 53, Issue:8 Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Azacitidine; Cohort Studies; Cytogenetics; Disease Progression; Female; Humans; Male; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome	2012
Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma. PloS one, 2012, Volume: 7, Issue:2 Topics: Azacitidine; Base Sequence; Bone Marrow; Cell Line, Tumor; Disease Progression; DNA Methylation; Gene Silencing; Humans; Intercellular Signaling Peptides and Proteins; Molecular Sequence Data; Multiple Myeloma; Neoplasm Staging; Promoter Regions, Genetic; Transcription, Genetic; Wnt Proteins; Wnt Signaling Pathway	2012
Loss of desmocollin 1-3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma. International journal of colorectal disease, 2012, Volume: 27, Issue:11 Topics: Aged; Aged, 80 and over; Azacitidine; CDX2 Transcription Factor; Cell Line, Tumor; Colorectal Neoplasms; Desmocollins; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Homeodomain Proteins; Humans; Immunohistochemistry; Male; Multivariate Analysis; Paired Box Transcription Factors; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis	2012
Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes. Leukemia & lymphoma, 2012, Volume: 53, Issue:12 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Bone Marrow; Bone Marrow Cells; Decitabine; Disease Progression; Female; Hemoglobins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Young Adult	2012
Erythroblastic sarcoma, an extremely rare variant of myeloid sarcoma. Human pathology, 2012, Volume: 43, Issue:11 Topics: Abnormal Karyotype; Adenocarcinoma; Aged; Azacitidine; Biopsy, Large-Core Needle; Bone Marrow; Bone Marrow Neoplasms; Bone Neoplasms; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Erythroblasts; Erythropoietin; Fatal Outcome; Humans; Lymph Nodes; Male; Myelodysplastic Syndromes; Rare Diseases; Rectal Neoplasms; Sarcoma, Myeloid	2012
Improving the outlook for myelodysplastic syndrome. Journal of the National Cancer Institute, 2012, Aug-22, Volume: 104, Issue:16 Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Myelodysplastic Syndromes; Phosphoproteins; Point Mutation; Prognosis; Ribonucleoprotein, U2 Small Nuclear; Risk Assessment; RNA Splicing; RNA Splicing Factors; Spliceosomes; Thalidomide	2012
Mining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasis. PloS one, 2012, Volume: 7, Issue:9 Topics: Animals; Azacitidine; Cell Line, Tumor; Disease Progression; Epigenesis, Genetic; Female; Gene Expression Profiling; Humans; Hydroxamic Acids; Karyotyping; Melanocytes; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Oligonucleotide Array Sequence Analysis; Phenotype; Risk; Skin Neoplasms	2012
Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia. Experimental hematology, 2013, Volume: 41, Issue:2 Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Catalysis; Cell Line, Tumor; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Induction; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Acute; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Second Primary; Promoter Regions, Genetic; Risk	2013
KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Kisspeptins; Male; Middle Aged; Molecular Sequence Data; Prognosis	2013
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Odds Ratio; Prognosis; Retrospective Studies; Risk Factors; Treatment Outcome	2013
CD81 is a candidate tumor suppressor gene in human gastric cancer. Cellular oncology (Dordrecht), 2013, Volume: 36, Issue:2 Topics: Apoptosis; Azacitidine; Base Sequence; Blotting, Western; Cell Cycle; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Molecular Sequence Data; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Stomach Neoplasms; Tetraspanin 28; Tumor Suppressor Proteins	2013
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. British journal of haematology, 2013, Volume: 160, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antimetabolites; Azacitidine; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Follow-Up Studies; Genes, p53; Humans; Incidence; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Prognosis; Risk; Treatment Outcome; Young Adult	2013
IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:12 Topics: Animals; Azacitidine; CD4 Lymphocyte Count; Chemokines; Decitabine; Dendritic Cells; Disease Progression; Humans; Interferon Regulatory Factors; Interleukin-17; Interleukins; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor Cross-Talk; Receptors, Chemokine; Spleen; T-Lymphocytes; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor Receptor-2	2012
Scedosporium apiospermum soft tissue infection as the initial presentation of acute myeloid leukemia: a case report. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Mar-01, Volume: 31, Issue:7 Topics: Aged, 80 and over; Amputation, Surgical; Antifungal Agents; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Humans; Leg Ulcer; Leukemia, Myeloid, Acute; Mycoses; Pancytopenia; Pyrimidines; Scedosporium; Soft Tissue Infections; Triazoles; Voriconazole	2013
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. European journal of haematology, 2013, Volume: 90, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Retrospective Studies	2013
Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. Cancer research, 2002, Aug-15, Volume: 62, Issue:16 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Proteins; Cell Transformation, Neoplastic; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Disease Progression; DNA-Binding Proteins; ErbB Receptors; Humans; Mouth Mucosa; Mouth Neoplasms; Polo-Like Kinase 1; Precancerous Conditions; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Receptors, Retinoic Acid; RNA, Messenger; Telomerase; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2002
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood, 2002, Oct-15, Volume: 100, Issue:8 Topics: Adult; Aged; Azacitidine; Cell Cycle Proteins; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Female; Genes, Tumor Suppressor; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Tumor Suppressor Proteins	2002
Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype. Leukemia, 2003, Volume: 17, Issue:4 Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Galectins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Lymphoma, T-Cell; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Radiation-Induced; Oligonucleotide Array Sequence Analysis; RNA, Messenger; RNA, Neoplasm; Specific Pathogen-Free Organisms; Thymus Neoplasms; Tumor Cells, Cultured	2003
Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. International journal of cancer, 2003, Sep-10, Volume: 106, Issue:4 Topics: Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Probes; Down-Regulation; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Liver Neoplasms; Melanoma; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tissue Inhibitor of Metalloproteinase-3; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured; Uveal Neoplasms	2003
Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas. International journal of oncology, 2003, Volume: 23, Issue:2 Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Azacitidine; Carcinoma, Squamous Cell; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; DNA, Neoplasm; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Leucine Zippers; Loss of Heterozygosity; Male; Microsatellite Repeats; Middle Aged; Mouth Neoplasms; Nerve Tissue Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Tumor Suppressor Proteins	2003
Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Apr-01, Volume: 10, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Division; Cell Line, Tumor; CpG Islands; Decitabine; Disease Progression; DNA Methylation; DNA, Complementary; Exons; Female; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Nerve Tissue Proteins; Polymorphism, Single-Stranded Conformational; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Sulfites; Synucleins; Time Factors	2004
CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer research, 2004, Sep-01, Volume: 64, Issue:17 Topics: Aged; Aged, 80 and over; Apoptosis; Azacitidine; Base Sequence; Cell Division; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, MDR; Humans; Male; Middle Aged; Molecular Sequence Data; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2004
Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality. Oncology reports, 2004, Volume: 12, Issue:5 Topics: Adenoma; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunoenzyme Techniques; Mouth Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Promoter Regions, Genetic; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serpins; Stomach Neoplasms; Tumor Suppressor Protein p53	2004
Methylation analysis of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma. Leukemia research, 2005, Volume: 29, Issue:1 Topics: Adenomatous Polyposis Coli Protein; Azacitidine; Cell Line, Tumor; CpG Islands; Disease Progression; DNA Methylation; Humans; Leukemia-Lymphoma, Adult T-Cell; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction	2005
Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Carcinoma; Cell Differentiation; Cell Line, Tumor; Colon; Colorectal Neoplasms; Disease Progression; DNA Methylation; DNA Primers; DNA-Binding Proteins; Female; Humans; Immunohistochemistry; Inhibitor of Differentiation Protein 2; Male; Middle Aged; Models, Genetic; Neoplasms; Polymerase Chain Reaction; Prognosis; Repressor Proteins; Risk; RNA, Messenger; Sequence Analysis, DNA; Sulfites; Time Factors; Transcription Factors	2004
Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-15, Volume: 11, Issue:2 Pt 1 Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Carcinoma, Renal Cell; CpG Islands; Cytoskeletal Proteins; Decitabine; Desmoplakins; Disease Progression; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Female; gamma Catenin; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Mutation; Prognosis; Promoter Regions, Genetic; Survival Rate	2005
Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis, 2005, Volume: 26, Issue:11 Topics: Animals; Azacitidine; Biomarkers, Tumor; Cell Cycle Proteins; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melanoma, Experimental; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; RNA, Messenger; RNA, Neoplasm; Skin Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured	2005
Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer. The Prostate, 2006, Feb-01, Volume: 66, Issue:2 Topics: Androgens; Azacitidine; Cell Line, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 2; Decitabine; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Methyltransferases; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Spectral Karyotyping	2006
Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene, 2006, May-18, Volume: 25, Issue:21 Topics: Adenocarcinoma; Azacitidine; Barrett Esophagus; beta Catenin; Cell Division; Cell Line, Tumor; CpG Islands; Decitabine; Disease Progression; DNA Methylation; DNA, Neoplasm; Esophageal Neoplasms; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, APC; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Mucous Membrane; Neoplasm Proteins; Precancerous Conditions; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction; Transfection; Wnt Proteins; Wnt2 Protein	2006
Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biological chemistry, 2006, Volume: 387, Issue:6 Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Calcitriol; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Kallikreins; Promoter Regions, Genetic; Transcription, Genetic	2006
Estrogen receptor-alpha methylation predicts melanoma progression. Cancer research, 2006, Jul-01, Volume: 66, Issue:13 Topics: Age Factors; Azacitidine; Decitabine; Disease Progression; DNA Methylation; DNA, Neoplasm; Estrogen Receptor alpha; Female; Gene Silencing; Humans; Hydroxamic Acids; Male; Melanoma; Middle Aged; Neoplasm Staging; Promoter Regions, Genetic; Sex Factors	2006
Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction. International journal of cancer, 2006, Nov-15, Volume: 119, Issue:10 Topics: Adenosine Triphosphatases; Antimetabolites, Antineoplastic; Apolipoproteins; Apolipoproteins D; Astrocytoma; Azacitidine; Biomarkers, Tumor; Brain Neoplasms; Cation Transport Proteins; Cell Adhesion Molecules, Neuronal; Decitabine; Disease Progression; DNA Methylation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Glycoproteins; Guanine Nucleotide Exchange Factors; Histone Deacetylases; Humans; Hydroxamic Acids; Membrane Transport Proteins; Nerve Tissue Proteins; Nuclear Proteins; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Protein Synthesis Inhibitors; Proteins; Reverse Transcriptase Polymerase Chain Reaction	2006
Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Nov-15, Volume: 12, Issue:22 Topics: Adenocarcinoma; Aged; Azacitidine; Barrett Esophagus; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; Esophageal Diseases; Esophageal Neoplasms; Female; Genetic Markers; Glycoproteins; Humans; Male; Middle Aged; Polymerase Chain Reaction; Precancerous Conditions	2006
Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jan-01, Volume: 13, Issue:1 Topics: Adenoviridae; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; DNA, Complementary; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Neoplasm Proteins; Oxidoreductases; RNA Interference; Time Factors; Tumor Suppressor Proteins; WW Domain-Containing Oxidoreductase	2007
[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2007, Volume: 38, Issue:1 Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Disease Progression; DNA Methylation; Genetic Predisposition to Disease; Humans; Leukemia; Myelodysplastic Syndromes; Oxides	2007
Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas. Haematologica, 2007, Volume: 92, Issue:4 Topics: Azacitidine; Cell Line, Tumor; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Decitabine; Disease Progression; DNA Methylation; DNA, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; GTPase-Activating Proteins; Humans; Lymphoma, Mantle-Cell; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Promoter Regions, Genetic; Transcription, Genetic; Translocation, Genetic	2007
Progressive silencing of p14ARF in oesophageal adenocarcinoma. Journal of cellular and molecular medicine, 2009, Volume: 13, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Barrett Esophagus; Base Sequence; Cell Line; Decitabine; Disease Progression; Epithelial Cells; Esophageal Neoplasms; Female; Gene Silencing; Histones; Humans; Male; Methylation; Middle Aged; Molecular Sequence Data; Survival Rate; Tumor Suppressor Protein p14ARF	2009
Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma. International journal of oncology, 2008, Volume: 32, Issue:5 Topics: Adult; Aged; Azacitidine; Cadherins; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Promoter Regions, Genetic; Tumor Suppressor Proteins	2008
Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clinical & experimental metastasis, 1997, Volume: 15, Issue:5 Topics: Antigens, Neoplasm; Azacitidine; Clone Cells; Decitabine; Disease Progression; Eye Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma-Specific Antigens; Neoplasm Metastasis; Neoplasm Proteins; Tumor Cells, Cultured	1997
Correlation between growth control, neoplastic potential and endogenous connexin43 expression in HeLa cell lines: implications for tumor progression. Carcinogenesis, 2000, Volume: 21, Issue:2 Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Clone Cells; Coculture Techniques; Connexin 43; Decitabine; Disease Progression; DNA Methylation; Fibroblasts; Gap Junctions; Gene Expression Regulation, Neoplastic; Gene Silencing; HeLa Cells; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Recombinant Fusion Proteins; RNA, Messenger; RNA, Neoplasm; Tetracycline; Transcriptional Activation; Transfection	2000
Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis. International journal of cancer, 2002, Jan-10, Volume: 97, Issue:2 Topics: Amino Acid Sequence; Animals; Antigens, Neoplasm; Azacitidine; Base Sequence; Blotting, Northern; Chromosome Mapping; Cloning, Molecular; Decitabine; Disease Progression; DNA Modification Methylases; DNA Primers; DNA, Complementary; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Molecular Sequence Data; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Testis; Transfection; Tumor Cells, Cultured	2002